- €3.45bn
- €4.02bn
- €1.20bn
Brief: Diasorin Receives Us' FDA 510(K) Clearance And Clia Waiver For Liaison Nes Group A Streptococcus (Gas) Assay
Deutsche Bank cuts Diasorin to 'sell', sees company targets as stretched
Italy - Factors to watch on June 5
Italy's DiaSorin jumps after Betaville reports possible takeover interest
Europe Research Roundup: Aj Bell, Greencore, S&U
Brief: Diasorin exec says 2026 guidance doesn't factor in prolonged Middle East war
Brief: Diasorin to reinvest cash for growth, dividends or possible M&A, chairman says
Italy's Diasorin confirms 2026 target, sees 6-8% sales growth until 2030 (updated)
Italy's Diasorin confirms 2026 guidance, sees 6-8% yearly sales growth until 2030
Brief: Diasorin Sees 2030 Adj EBITDA Margin At 34%-35%
Italy - Factors to watch on May 20
Diasorin jumps as earnings fall less than expected, backs outlook
Italy - Factors to watch on May 11
Italy's DiaSorin posts 28% Q1 profit decline on weak flu season
Brief: Diasorin Q1 Adj. EBITDA EUR 90 Mln
Italy - Factors to watch on May 8
Italy - Factors to watch on April 29
DiaSorin falls as Qiagen cuts outlook on QuantiFERON weakness
DiaSorin slides on expectation of 'another year with no margin growth'